BioNTech SE (BNTX) AI Stock Analysis

BioNTech SE is a Mainz, Germany-based biotechnology company pioneering mRNA therapies, CAR-T treatments, and immunotherapies for oncology and infectious diseases. Its clinical pipeline features FixVac candidates such as BNT111 for melanoma and BNT116 for non-small cell lung cancer, alongside neoantigen-specific therapies like Autogene cevumeran (BNT122). The company also advances CAR-T programs including BNT211, checkpoint immunomodulators GEN1046 and GEN1042, monoclonal antibody BNT321, and prophylactic vaccines for COVID-19 and influenza. BioNTech collaborates with major industry partners, including Pfizer Inc., Genentech, Inc., Sanofi S.A., Regeneron Pharmaceuticals, and Shanghai Fosun Pharmaceutical.

Following peak pandemic demand that drove FY2021 revenue to $18.98B, top-line sales contracted to $3.82B in FY2023 and $2.75B in FY2024. In FY2025, revenue edged up 0.2% to $2.76B, but the net loss widened to -$1.09B with an operating margin of -22.6%, reflecting R&D expense of $2.02B. For the trailing twelve months ended June 30, 2026, revenue stood at $2.65B with an operating margin of -806.6% and diluted EPS of -$7.83. In the latest quarter ended June 30, 2026, quarterly revenue fell 59.5% year-over-year, while quarterly earnings dropped 43.2%.

BioNTech maintains a balance sheet with $9.74B in cash and short-term investments against $316.0M in total debt as of June 30, 2026, yielding net cash of $9.42B. The company closed the quarter with a current ratio of 7.85 and a debt-to-equity ratio of 0.02 against $17.75B in shareholders' equity. In FY2025, operating cash flow generated $438.0M and free cash flow reached $269.8M, supported by moderate capital expenditures of $168.2M. Share count decreased 2.5% over 5 years.

At a closing price of $87.71 on October 16, 2026, BioNTech carries a market capitalization of $22.03B and an enterprise value of $8.18B. The stock trades at a price-to-sales multiple of 8.3x and an enterprise-value-to-revenue multiple of 2.7x. Its forward P/E of 7.0x trades below the median of its US-listed Healthcare peers of 17.3x, while its EV/EBITDA of 110.8x trades well above the peer median of 12.0x. Over the past year, BNTX fell 16.5%, underperforming the SPY gain of 16.8%, and is down 64.1% over 5 years compared to an 83.0% gain for SPY.

Wall Street coverage includes 13 Strong Buy, 1 Buy, and 7 Hold recommendations, with zero Sell ratings. The mean price target of $117.07 implies upside of 33.5% from the last close of $87.71. For the current fiscal year ending December 31, 2026, consensus calls for revenue of $1.78B and an EPS estimate of -$4.71, with EPS beats over the last 4 quarters standing at 0. For the next fiscal year, 10 analysts project revenue of $1.79B and EPS of -$5.00. The next earnings date is November 3, 2026.

This page is an AI-written research summary of BioNTech SE (BNTX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BNTX income statement, BNTX balance sheet, BNTX key metrics, BNTX analyst forecast, BNTX chart. See the BNTX stock overview for the latest quote and news.